论文部分内容阅读
晚期胰腺癌病情凶险，预后恶劣，目前其系统治疗的临床研究总体的中位无疾病进展生存期（ PFS）约为5个月，中位总生存期（ OS）不超过1年。针对体力状况较好的患者，一线系统治疗临床获益后能否实施单一化疗药物或分子靶向药物的维持治疗，从而实现OS突破12个月的目标？胰腺癌根治性手术及术后辅助化疗的5年生存率不足25％，那么辅助化疗结束后是否可以进行维持治疗？本文就此临床实践中亟待解决的问题进行梳理，以期提供参考。“,”The prognosis of advanced pancreatic cancer is extremely poor. According to clinical trials concerned with first?line systemic therapy, the median progression?free survival ( PFS) was 5 months and median overall survival ( OS) was less than one year. To those patients benefited from first?line regimen and with good performance status, can we switch the therapeutic modality into a sin?gle cytotoxic or target agent. It is so called “maintenance therapy”?As concerned to pancreatic cancer patients received radical resec?tion, five?year survival rate was less than 25% even adjuvant therapy completed. May maintenance therapy continue with adjuvant set?ting aimed to prolong disease?free survival?We combed these burning problems to be solved practically in order to provide clinical ref?erence.